Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Part of paid clinical trials in New York, New York.
- Sponsor
- Pfizer
- Study ID
- NCT04721821
- Status
- Completed
Conditions
- Arthritis Rheumatoid
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tofacitinib — DRUGPatients who received Tofacitinib for RA
Study Details
This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.
Key Dates
- Start date
- Jan 22, 2021
- Status verified
- Oct 2023
- Primary completion
- Nov 29, 2021
- Completion
- Nov 29, 2021
Study Design
- Enrollment
- 7,807 participants (actual)
Arms
- Arm: Patients with Rheumatoid Arthritis (RA)
Primary Outcome Measure
Number of Participants Who Achieved Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) at Month 6: Tofacitinib Overall Versus TNFis Overall [ Time Frame: Month 6 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Pfizer | New York | New York | 10017 | - |
Find similar trials in New York, NY
By research site